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switch (1.08; p  0.01) and those with higher depression
scores (MADRS) experienced shorter time to switch
(0.97; p  0.02). Those receiving service through univer-
sity hospital experienced longer interval (3.19; p  0.01).
The computed hazard rate (0.68) indicates the risk of
switch is decreasing over time. CONCLUSIONS: Find-
ings indicate that symptoms and type of service delivery
site are significant in determining the switch from older
to newer agents. The shorter interval for those with
higher depression scores is expected and is probably re-
flective of clinical intervention aimed toward the amelio-
ration of negative symptoms. Interestingly, the longer
interval for those with higher side effect scores was con-
trary to expectation and may indicate that the motivating
influence to change is more related to the presentation of
primary disease state, rather than the reduction of sec-
ondary symptoms associated with the first generation
medications. The longer interval for those receiving care
in a university hospital setting is perplexing since it is
usually expected that medication adjustment will occur
during hospital stays. Further investigation of this phe-
nomenon may be aided by the inclusion of physician level
information, which is anticipated in upcoming analyses.
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OBJECTIVES: While most current antidepressant agents,
such as SSRIs and dual action agents are reasonably ef-
fective in ameliorating depressive symptomatology in
older patients, less is known about their impact on con-
current instrumental activities of daily living (IADL’s).
This study examines change in IADL’s, such as the capac-
ity to use the telephone, travel, shop, cook, do house-
work, handle money, or take medicine, from admission
to three-month post-discharge follow-up in geropsychiat-
ric patients (age 55 and older) with major depression
(ICD-9-CM codes 296.20-296.36) treated with fluoxe-
tine (n  77), mirtazapine (n  36), sertraline (n  145),
or venlaxafine (n  56). METHODS: Data were ob-
tained from the CQISM Outcomes Measurement Sys-
tem, which tracked patients admitted to geropsychiatric
inpatient programs in 111 general hospitals across 33
states between 1997–1999. IADL’s were measured by se-
lected items from the Duke OARS Multidimensional
Functional Assessment Questionnaire (Lawton & Brody,
1969). A Medication Usage Questionnaire was used to
track medications prescribed. One-way Analyses of Vari-
ance and if significant, Tukey’s pairwise comparisons
were used to compare medication groups. RESULTS: At
admission, patients exhibited moderate to severe inability
to independently carry out IADL’s (Mean score of 14 to
15 out of 21). Medication groups were indistinguishable
on change scores in overall IADL’s from time of admis-
sion to follow-up. On average, patients showed no
change in their ability to carry out IADL’s during this
time period, despite an improvement in level of depres-
sion, as measured by the collateral version of the Geriat-
ric Depression Scale (Nitcher, Burke, Roccaforte, &
Wengel, 1993). CONCLUSIONS: Antidepressant agents
in this analysis were associated with modest improve-
ment in IADL’s as assessed by the Duke OARS Multi-
demsional Functional Assessment in Older Adults. New
treatment modalities that improve IADL’s along with de-
pressive symptomatology in older patients would be ben-
eficial. Further controlled studies are needed to better un-
derstand these findings.
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OBJECTIVES: Numerous antidepressant agents are
available to treat geropsychiatric patients with depres-
sion. While most current agents are reasonably effective
in ameliorating depressive symptomatology, less is known
about the impact of these agents on concurrent maladap-
tive behaviors. This study examines change in sixteen
such behaviors from admission to discharge to three-
month post-discharge follow-up in geropsychiatric pa-
tients (age 55 and older) with major depression (ICD-9-
CM codes 296.20-296.36) treated with fluoxetine (n 
292), mirtazapine (n  288), sertraline (n  744), or ven-
laxafine (n  289). METHODS: Data were obtained
from the CQISM Outcomes Measurement System,
which tracked patients admitted to geropsychiatric inpa-
tient programs in 111 general hospitals across 33 states
between 1997–1999. Maladaptive behaviors were mea-
sured by the Psychogeriatric Dependency Rating Scale
(PGDRS) (Wilkinson & Graham-White, 1980) and a
Medication Usage Questionnaire was used to track medi-
cations prescribed at admission, discharge, and follow-
up. One-way Analyses of Variance and if significant,
Tukey’s pairwise comparisons were used to compare
medication groups. RESULTS: At admission, patients ex-
hibited mild to moderate evidence of maladaptive behav-
iors (Mean PGDRS overall score of 20 out of 48). Medi-
cation groups were indistinguishable on change scores in
overall maladaptive behaviors from time of admission to
discharge (average length of stay around 16 days), dis-
charge to follow-up, or admission to follow-up. On aver-
age, patients showed a very modest improvement (1–2
points) on the PGDRS from admission to discharge,
modest decline from discharge to follow-up (0–2 points),
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and no change to modest improvement from admission
to follow-up (0–1 points). CONCLUSIONS: Antidepres-
sant agents in this analysis were associated with modest
improvement in maladaptive behavior as assessed by the
PDGRS. New treatment modalities that improve mal-
adaptive behavior along with depressive symptomatology
in older patients would be beneficial. Further controlled
studies are needed to better understand these findings.
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OBJECTIVES: An array of antidepressant agents are
available in the treatment of geropsychiatric patients with
depression. While most current agents, such as the selec-
tive serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxe-
tine; sertraline) and agents acting upon both serotonin
and norepinephrine (e.g., mirtazapine; venlaxafine), are
reasonably effective in ameliorating depressive symptom-
atology, less is known about the impact of these agents
on other common areas of deficit in older depressed pa-
tients, such as cognition. This study examines change in
cognitive functioning in geropsychiatric patients (age 55
and older) with major depression (ICD-9-CM codes
296.20-296.36) treated with fluoxetine (n  269), mir-
tazapine (n  275), sertraline (n  713), or venlaxafine
(n  259). METHODS: Data were obtained from the
CQISM Outcomes Measurement System, a Joint Com-
mission of Accredited Hospital Organizations (JCAHO)
ORYX accepted performance improvement system,
which tracked patients admitted to geropsychiatric inpa-
tient programs in 111 general hospitals across 33 states
between 1997–1999. Cognitive functioning was mea-
sured at admission and discharge using the Mini-Mental
State Examination (MMSE) (Folstein, Folstein, & McHugh,
1975). A Medication Usage Questionnaire was used to
track medications prescribed to patients just prior to ad-
mission and at discharge. One-way Analyses of Variance
and if significant, Tukey’s pairwise comparisons, were
used to compare medication groups. RESULTS: At ad-
mission, patients exhibited moderate evidence of cogni-
tive impairment (Mean MMSE score of 21 out of 30).
Medication groups were indistinguishable on change
scores in cognitive functioning from time of admission to
discharge (average length of stay around 16 days). The
average change score on the MMSE was 1.1 to 1.6 points,
suggesting very mild improvement. CONCLUSIONS: Anti-
depressant agents in this analysis were associated with
modest improvement in cognitive functioning as assessed
by the MMSE. New treatment modalities that improve
cognition along with depressive symptomatology in older
patients would be beneficial.
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OBJECTIVES: To compare the change in health care uti-
lization and costs from one year before (preperiod) and
one year after (postperiod) starting treatment with ris-
peridone or olanzapine in schizophrenia patients in a
Veterans Administration population. METHODS: Pa-
tients with a diagnosis of schizophrenia (ICD-9 CM code
295) in the preperiod, who had an initial prescription for
risperidone or olanzapine dispensed between 3/97 and
3/99, were included. Patients who received any atypical
antipsychotic in the preperiod were excluded. Compari-
sons of average change in utilization and cost from the
preperiod to the postperiod were made between the
groups for: inpatient hospitalizations, outpatient clinic
visits, medications, and total health care cost. Analysis of
covariance was used to analyze the data using age, gen-
der, and race as covariates. RESULTS: 304 patients in
the olanzapine group and 344 in the risperidone group
were included. The olanzapine group had significantly
more inpatient admissions per patient (0.09 vs. 0.24,
p  0.026), longer inpatient lengths of stay (4.3 days
vs. 4.2 days, p  0.004), and higher cost of inpatient
admissions ($2735 vs. $3226, p  0.003) than the ris-
peridone group. There was a significantly lower cost of
antipsychotic for the risperidone group than for the olan-
zapine group ($650 vs. $1660, p  0.001). The mean
daily doses were 3.4 mg of risperidone and 12.0 mg of
olanzapine. The olanzapine group also had a significantly
higher change in cost for all drugs ($1492 vs. $683, p 
0.001) and all health care costs ($5,665 vs. $1,167, p 
0.001) than the risperidone group. CONCLUSIONS:
The changes in total health care costs, number, length of
stay, and cost of inpatient admissions, and medication
costs for risperidone-treated patients were significantly
lower compared with olanzapine-treated patients.
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OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is the most commonly diagnosed psychiatric
disorder among children in the US. However, the social
